Association of Regular Antithrombotic Drug Use with the Risk of Non-Gallstone Acute Pancreatitis: A Prospective Cohort Study

Chenyang Wei[1,2], Jinyu Zhao[1,2], Ningning Mi[1,2,3], Pengfei Li[1,2], Zhengping An[1,2], Sheng Chen[1,2], Yanyan Lin[1,2], Ping Yue[1,2], Jinqiu Yuan[3*], Wenbo Meng[1,2*]

[1]The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China

[2]Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China

[3]Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China

*These authors are the corresponding authors

Correspondence

Wenbo Meng, Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China. Email: mengwb@lzu.edu.cn

Jinqiu Yuan, Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China. Email: yuanjq5@mail.sysu.edu.cn

Words count for the abstract: 275

Words count for the main text: 3197

Abstract

Background: Antithrombotic drugs are widely used for cardiovascular disease prevention, but their association with non-gallstone acute pancreatitis (NGAP) remains unclear.

Objective: To prospectively investigate the association between regular antithrombotic drug use and the risk of incident NGAP.

Design: Prospective cohort study.

Participants: A total of 431,754 participants from the UK Biobank who were free of cancer, gallstone disease, and pancreatitis at baseline.

Main Measures: The exposure was defined as regular antithrombotic use, assessed via a baseline questionnaire. The primary outcome was defined as incident NGAP, identified from hospital records (ICD-10 code K85) after excluding concurrent gallstone disease.

Key Results: During a median follow-up of 13.73 years, a total of 2,189 incident cases of NGAP were recorded. After full adjustment for demographic, lifestyle, and clinical factors, antithrombotic use was associated with a 31% increased risk (HR = 1.31, 95% CI: 1.08–1.61, p = 0.007). Risk varied by drug type: clopidogrel was associated with a 53% increased risk (HR = 1.53, 95% CI: 1.08–2.16, p = 0.016)), while warfarin showed a non-significant trend (HR = 1.32, 95% CI: 0.97–1.80, p = 0.076); Subgroup analysis showed that the risk associated with warfarin was confined to non-diabetic individuals (P-interaction = 0.015; HR in non-diabetics = 1.64). This effect modification was specific to warfarin. The results were robust to sensitivity analyses, including the exclusion of

early events and propensity score matching.

Conclusions: In this prospective cohort, antithrombotic drug use was associated with an increased NGAP risk, which was driven by clopidogrel and, for warfarin, was specific to individuals without diabetes.

Keywords: Antithrombotic; Acute pancreatitis; Risk factors; Warfarin; Clopidogrel; Type 2 diabetes mellitus; Hyperlipidemia; cohort study

Introduction

Acute pancreatitis (AP) is an acute abdominal condition triggered by the abnormal activation of pancreatic enzymes, leading to pancreatic self-digestion and localized inflammation.[1] In severe cases, it can progress to systemic inflammation and multiple organ failure, with a mortality rate as high as 85% .[2] The etiological spectrum of AP exhibits significant geographical variation: in Western countries, gallstone disease is the leading cause, followed by alcoholic and hypertriglyceridemia-induced pancreatitis. However, in Asian countries, including China, hypertriglyceridemia accounts for a substantially higher proportion of cases.[3] The rapidly increasing prevalence of hypertriglyceridemia-related AP has made it a global health concern that demands attention.[4,5]

Besides the traditional causes, medications are also recognized as potential inducers of AP.[6,7] Antithrombotic agents have drawn particular attention due to their widespread use in patients with cardiovascular diseases.[8,9] However, evidence regarding the association between these drugs and the risk of AP remains notably controversial, with no consensus reached to date. A protective viewpoint suggests potential benefits through mechanisms such as inhibiting pancreatic microthrombosis and improving microcirculatory disturbances. Supporting this, animal studies have demonstrated that pretreatment with low-dose warfarin can alleviate ischemia/reperfusion-induced pancreatic injury via this mechanism.[10] A recent large-scale clinical study also found that among patients with

established AP, the use of low-dose aspirin—primarily an antiplatelet agent—was associated with lower mortality and reduced risk of complications.[11] Conversely, some observational studies have indicated uncertain or even increased risks.[12–15] Potential mechanisms for harm may involve drug-induced disturbances in pancreatic microcirculation, leading to local ischemia or micro-hemorrhagic events. This pathophysiological link is well-established, as acute pancreatitis is characterized by microvascular alterations—such as dilation, congestion, and necrosis—that underscore the system's vulnerability.[16] Reflecting this uncertainty, major international guidelines advise caution and do not recommend prophylactic anticoagulation as a standard treatment for severe acute pancreatitis (SAP).[17,18] This conflicting body of evidence creates a dilemma for clinicians managing the substantial population of patients with cardiovascular diseases who require long-term antithrombotic therapy, making it challenging to assess their potential AP risk.

In our opinion, it is imperative to clarify the relationship between antithrombotic medication use and the risk of acute pancreatitis (AP). Should these drugs be confirmed as a risk factor, their cardiovascular benefits must be rigorously weighed against the AP risk in clinical decision-making, prompting greater caution among prescribers. Conversely, evidence of a protective effect would justify further research into mechanisms such as enhanced pancreatic microcirculation or suppression of thromboinflammation. Consequently, we conducted a prospective analysis of this

association within a large cohort of 431,754 individuals.

Methods

Study Population

The study population was derived from the UK Biobank (UKB), a large prospective cohort comprising over 500,000 participants aged 37-73 years. The cohort was established between 2006 and 2010 across 22 assessment centers in England, Wales, and Scotland. Participants are followed up with regularly for data updates. At recruitment, all individuals completed a baseline questionnaire and underwent assessments that included physical measurements, as well as detailed information on lifestyle and medication use. Further details regarding the UK Biobank cohort have been published elsewhere.[19] We excluded participants with a diagnosis of cancer, gallstone disease, or acute pancreatitis at baseline. Furthermore, to minimize potential confounding by gallstones, individuals who developed acute pancreatitis during follow-up and had a prior gallstone diagnosis were also excluded, along with those lacking follow-up data. The final analytical cohort consisted of 431,754 participants (see Supplementary Figure 1). All diagnoses were based on International Classification of Diseases-10 (ICD-10) diagnostic criteria.

Assessment of Main Exposure

Main Exposure: The main exposure in this study was defined as regular use of antithrombotic drugs at baseline, including anticoagulants and antiplatelet drugs. Specific

medications considered were warfarin, low-dose aspirin, clopidogrel, and dipyridamole. At baseline, regular use of antithrombotic drugs was first assessed from participants using a touchscreen questionnaire and then confirmed during verbal interviews with trained staff. In the touchscreen questionnaire, participants were asked, “Do you regularly take any other prescription medications?” “Regular use” was defined as taking the medication on most days of the previous 4 weeks. If the participant selected “Yes” or “Unsure,” the interviewer would ask: “In the touchscreen, you said you are taking regular prescription medications. Can you now tell me what these are?” Information on the use of antithrombotic drugs was recorded using a coded list. The recorded types of antithrombotic drugs mainly included warfarin, low-molecular-weight heparin, low-dose aspirin, clopidogrel, and dipyridamole. Information about doses and duration of antithrombotic agents was not collected. Detailed questions regarding the use of antithrombotic agents can be found on the UK Biobank website.[20]

Outcomes: NGAP was confirmed through hospital records linked to the Health and Social Care Information Centre (England and Wales) and the National Health Service Central Register (Scotland). The diagnosis of acute pancreatitis was coded according to the International Classification of Diseases (ICD-10), recorded as K85.

Assessment of Covariates

At enrollment, information on covariates was collected through a touchscreen

questionnaire and face-to-face interviews, covering socio-demographic characteristics, anthropometric measurements, lifestyle factors, medical history, and medication use. Specifically, the data included: (1) socio-demographic factors: age, sex, ethnicity and socioeconomic status (measured using the Index of Multiple Deprivation, IMD, directly obtained from the UK Biobank); (2) anthropometric data: height and weight, with body mass index (BMI) calculated as kg/m^2; (3) lifestyle factors: smoking status, alcohol intake, physical activity (assessed using the short-form International Physical Activity Questionnaire, IPAQ), and healthy diet (defined according to American Heart Association guidelines; Supplementary Table 1); (4) medical history: type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease; (5) medication use: nonsteroidal anti-inflammatory drugs (NSAIDs), hypolipidemic drugs, multivitamin and mineral supplements.

Statistical Analysis

Baseline characteristics are presented as means (standard deviation, SD) for continuous variables and as counts (percentages) for categorical variables. Person-years of follow-up were calculated from the date of assessment for each participant until the first diagnosis of acute pancreatitis, death, or the end of follow-up (May 31, 2022), whichever came first.

To illustrate the differences in cumulative incidence, curves for NGAP were generated

comparing non-users with users of antithrombotic drugs, anticoagulants, antiplatelet agents, and specific medications. A crude model was first constructed to examine the association between antithrombotic use and the risk of NGAP. Three adjusted models were then established: Model 1 adjusted for age, gender, ethnicity, and IMD; Model 2 further adjusted for BMI, smoking, alcohol intake, physical activity, and healthy diet; Model 3 additionally adjusted for type 2 diabetes, hypertension, hyperlipidemia, NSAID use, hypolipidemic drugs, multivitamin use, and mineral supplement intake. The proportional hazards assumption was verified using Schoenfeld residuals for all models, with no violations detected.

To investigate whether specific drug types drove the observed association, subgroup analyses were conducted according to pharmacological class (anticoagulants or antiplatelet agents) and by individual drugs (warfarin, aspirin, clopidogrel, and dipyridamole). Results from the most fully adjusted model (Model 3) are reported as the primary findings in this study.

We evaluated the potential moderating effects of age, sex, BMI, smoking status, alcohol intake, physical activity, healthy diet, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic drug intake, multivitamin and mineral supplement use, using stratified analysis and interaction testing with a likelihood ratio test in subgroup analyses. Given that type 2 diabetes and hyperlipidemia suggested potential effect

modification in the overall analysis, we also tested their interaction effects in the aforementioned stratified medication analyses.

To assess the robustness of our findings, we performed several sensitivity analyses: (1) further adjustment for history of cardiovascular diseases in Model 3 (as Model 4); (2) exclusion of participants who developed the outcome within the first year of follow-up to minimize reverse causality; and (3) a propensity score matching (PSM) analysis to evaluate the effect of antithrombotic medication on NGAP.

All analyses were conducted using R version 4.5.1. A two-tailed P value < 0.05 was considered statistically significant.

Results

Baseline Characteristics of Participants

Table 1 presents the baseline characteristics of the study participants stratified by antithrombotic medication use. The study included 431,754 participants, of whom 11,140 were antithrombotic medication users. Among the users, 4,452 used anticoagulants only, 6,610 used antiplatelet agents only, and 78 used both antiplatelet agents and anticoagulants. In terms of specific medications, 4,397 used warfarin, 2,514 used low-dose aspirin, 950 used dipyridamole, 2,818 used clopidogrel, and 93 used both aspirin and clopidogrel. Antithrombotic medication users were more likely to be older, male,

smokers, alcohol consumers, and have a higher prevalence of comorbidities, including type 2 diabetes, hypertension, and hyperlipidemia.

Table 1 Baseline characteristics of participants by antithrombotic use in the UK Biobank

	Antithrombotic use		**Overall**
	No	**Yes**	
Number of participants	(N=420614)	(N=11140)	(N=431754)
Anticoagulant only	/	4,452	/
Warfarin	/	4,397	/
Antiplatelet only	/	6,610	/
Low-dose aspirin	/	2,514	/
Dipyridamole	/	950	/
Clopidogrel	/	2,818	/
Aspirin and Clopidogrel	/	93	/
Both anticoagulant and antiplatelet	/	78	/
Mean (SD)age	56.2 (8.10)	61.7 (6.26)	56.3 (8.11)
Male	195105 (46.4%)	7799 (70.0%)	202904 (47.0%)
White	396396 (94.2%)	10502 (94.3%)	406898 (94.2%)
Mean (SD) Index of multiple deprivation	17.2 (13.8)	19.4 (15.3)	17.2 (13.8)
Mean (SD)BMI	27.3 (4.71)	29.2 (5.18)	27.4 (4.73)
Smoking	187613 (44.6%)	6454 (57.9%)	194067 (44.9%)
Drinking	/	/	/
Never	79126 (18.8%)	2810 (25.2%)	81936 (19.0%)
Low	46553 (11.1%)	1104 (9.9%)	47657 (11.0%)
Moderate	207958 (49.4%)	4751 (42.6%)	212709 (49.3%)
High	86632 (20.6%)	2461 (22.1%)	89093 (20.6%)
MET_g	/	/	/
high	135361 (32.2%)	3047 (27.4%)	138408 (32.1%)
low	59600 (14.2%)	1929 (17.3%)	61529 (14.3%)
moderate	132826 (31.6%)	3379 (30.3%)	136205 (31.5%)
healthyDiet	212118 (50.4%)	5768 (51.8%)	217886 (50.5%)
NASIDS	69906 (16.6%)	699 (6.3%)	70605 (16.4%)
Hypolipidemic drug	71717 (17.1%)	8142 (73.1%)	79859 (18.5%)
Vitamin	63113 (15.0%)	1636 (14.7%)	64749 (15.0%)
Mineral	91240 (21.7%)	1596 (14.3%)	92836 (21.5%)

Diabetes	34044 (8.1%)	3028 (27.2%)	37072 (8.6%)
Hypertension	305680 (72.7%)	9819 (88.1%)	315499 (73.1%)
Hyperlipidemia	201352 (47.9%)	9363 (84.0%)	210715 (48.8%)
Myocardial Infarction	16671 (4.0%)	439 (3.9%)	17110 (4.0%)
Coronary Heart Disease	22737 (5.4%)	599 (5.4%)	23336 (5.4%)
PVD	4624 (1.1%)	136 (1.2%)	4760 (1.1%)
AF	6987 (1.7%)	188 (1.7%)	7175 (1.7%)
Stroke	6638 (1.6%)	187 (1.7%)	6825 (1.6%)

PVD: myocardial infarction, AF: peripheral vascular disease,

NSAIDs: non-steroidal anti-inflammatory drugs,

Values are numbers (percentages) unless stated otherwise.

IMD： Index of Multiple Deprivation.

Antithrombotic Drugs Use and the Risk of NGAP

During a median follow-up of 13.73 years, 2,189 new cases of NGAP were recorded, including 109 cases in the antithrombotic drug user group and 2,080 cases in the non-user group. Compared with non-users, a higher cumulative incidence of acute pancreatitis was observed in users of antithrombotic drugs, particularly among users of anticoagulants and clopidogrel (Figure 1).

Figure 1 Cumulative Incidence of NGAP Among Users of Antithrombotic Drugs, Antiplatelet or Anticoagulant Drugs, and Specific Agents Compared with Non-Users.


A
Antithrombotic Drugs
Users: HR 1.15 (95%CI 1.08–1.22)
Non–users: Reference
Cumulative Incidence of NGAP(%)
1.50%
1.00%
0.50%
0.00%
0
2.5
5
7.5
10
12.5
15
Number at risk
420614 418449 414654 409257 402365 374892 31804
11140 10900 10570 10117 9561 8496 552
0.0 2.5 5.0 7.5 10.0 12.5 15.0
Time to event (Years)
B
Drug Categories
Antiplatelet: HR 1.27 (95%CI 0.98–1.64)
Anticoagulant: HR 1.37 (95%CI 1.01–1.86)
Non–users: Reference
Cumulative Incidence of NGAP (%)
1.50%
1.00%
0.50%
0.00%
0
2.5
5
7.5
10
12.5
15
Number at risk
6610 6495 6335 6094 5797 5215 326
4452 4330 4167 3958 3708 3237 222
420614 418449 414654 409257 402365 374892 31804
0.0 2.5 5.0 7.5 10.0 12.5 15.0
Time to event (Years)
C
Specific Antithrombotic Drugs
Clopidogrel: HR 1.53 (95%CI 1.08–2.16)
Warfarin: HR 1.32 (95%CI 0.97–1.80)
Aspirin: HR 1.02 (95%CI 0.65–1.61)
Dipyridamole: HR 0.95 (95%CI 0.45–2.00)
Non–users: Reference
Cumulative Incidence of NGAP (%)
1.50%
1.00%
0.50%
0.00%
0
2.5
5
7.5
10
12.5
15
Number at risk
Strata
2818 2765 2687 2572 2431 2146 153
4397 4277 4117 3911 3663 3197 219
2514 2487 2439 2379 2291 2132 128
950 931 902 854 802 695 32
420614 418449 414654 409257 402365 374892 31804
0.0 2.5 5.0 7.5 10.0 12.5 15.0
Time to event (Years)

All adjusted HRs were adjusted for the following covariates: age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake,multivitamin use and intake of mineral supplements.

HR, hazard ratio; CI, confidence interval; IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

In the crude model, the use of antithrombotic drugs was associated with a 74% increased risk of NGAP (HR 1.74, 95% CI 1.44-2.12, $p < 0.001$). After adjusting for age, sex, ethnicity, and IMD (Model 1), the HR was 1.66 (95% CI, 1.37-2.02; $p < 0.001$). The association attenuated somewhat but remained significant after further adjustment for lifestyle factors (Model 2) (HR, 1.44; 95% CI, 1.18-1.75; $p < 0.001$). In Model 3, which was further adjusted for comorbidities and medication use, the result did not change substantially (HR 1.31, 95% CI: 1.08-1.61, $p = 0.007$) (Table 2). In the analysis by pharmacological class, anticoagulant use demonstrated a significantly increased risk (HR = 1.37, 95% CI: 1.01-1.86, $p = 0.040$). Specifically, warfarin showed a trend toward an increased risk, although it did not reach statistical significance (HR = 1.32, 95% CI: 0.97-1.80, $p = 0.076$). Analysis for other anticoagulants could not be performed or yielded imprecise results due to limitations in sample size. The overall association for antiplatelet agents was at the margin of statistical significance (HR = 1.27, 95% CI: 0.98-1.64, $p = 0.071$). The use of clopidogrel was associated with a significantly increased risk (HR =

1.53, 95% CI: 1.08-2.16, p = 0.016), whereas neither aspirin (HR = 1.02) nor dipyridamole (HR = 0.95) showed a significant association (Figure 2).

Table 2 Associations between Antithrombotic use and risk of NGAP(n=431,754).

Variables	**Antithrombotic use**		**p-value**
	No （N=420,614）	**Yes (N=11,140)**	
Case/person-years	**2,080 / 5,652,141**	**109 / 139,161**	
IR (per 10,000 person-years) *	**3.68**	**7.83**	
Multivariate-adjusted HR (95% CI)			
Crude model [a]	1.00 (Reference)	1.74（1.44-2.12）	<0.001
model 1[b]	1.00 (Reference)	1.66（1.37-2.02）	<0.001
model 2[c]	1.00 (Reference)	1.44（1.18-1.75）	<0.001
model 3[d]	1.00 (Reference)	1.31（1.08-1.61）	0.007

[a] Unadjusted for covariates in the crude model.

[b] Age, gender, ethnicity, and the Index of Multiple Deprivation (IMD) were adjusted in model 1.

[c]BMI, smoking status, alcohol intake, physical activity, and dietary characteristics were additionally adjusted in model 2.

[d]Type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use, and intake of mineral supplements were further adjusted in model 3.

*IR, incidence rate; HR, hazard ratio; CI, confidence interval; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Figure 2 Analysis of the overall association between antithrombotic drug use and the risk of acute pancreatitis.



The model was adjusted for age, gender, ethnicity, the Index of Multiple Deprivation (IMD), BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic drug intake, multivitamin use, and mineral supplement intake.

Subgroup Analysis

The analysis, using overall antithrombotic medication as the exposure variable, revealed significant interaction effects for diabetes (p = 0.001) and hyperlipidemia (p = 0.044). Specifically, among the non-diabetic population, antithrombotic drug use was significantly associated with an increased risk of NGAP (HR=1.52, 95% CI: 1.19-1.96, P=0.001). However, this association was not observed in the diabetic population (HR = 1.08, 95% CI: 0.78-1.50, P = 0.644). The risk increase was more pronounced in the non-hyperlipidemic population (HR=1.96, 95% CI: 1.22-3.15, P=0.006), while the association was weaker and did not reach statistical significance in the hyperlipidemic population (HR=1.23, 95% CI: 0.99-1.53, P=0.063) (Figure 3).

Figure 3 Subgroup analyses of Antithrombotic use and the risk of acute pancreatitis.

Subgroup		Non-antithrombotic use		Antithrombotic use		Multivariate-adjusted HR(95% CI)	P_Value	P_Interaction
		Case	Person-years	Case	Person-years			
All people		2080	5652141	109	139161	1.37 (1.01-1.86)	0.040	
Age								0.910
	(35,55]	709	2525127	13	22793	1.19 (0.68-2.09)	0.546	
	(55,65]	947	2390321	54	73533	1.28 (0.96-1.70)	0.088	
	(65,75]	424	736693	42	42836	1.40 (1.00-1.94)	0.047	
Gender								0.889
	Female	1020	3054433	32	42928	1.33 (0.93-1.92)	0.118	
	Male	1060	2597708	77	96233	1.30 (1.02-1.66)	0.031	
BMI								0.146
	less than 25kg/m2	433	1908773	19	26826	1.71 (1.05-2.77)	0.03	
	25-30 kg/m2	870	2428087	34	61463	1.14 (0.80-1.62)	0.479	
	At least 30 kg/m2	777	1315281	56	50872	1.36 (1.03-1.80)	0.033	
Smoking								0.741
	Smoker	1101	2494024	69	78884	1.28 (0.99-1.65)	0.055	
	Non-smoker	968	3138831	40	59393	1.41 (1.02-1.96)	0.038	
Drinking								0.544
	Never	526	1051145	33	34437	1.32 (0.91-1.90)	0.138	
	Low	233	627878	8	13875	1.03 (0.50-2.12)	0.946	
	Moderate	907	2809485	48	59700	1.47 (1.09-1.99)	0.012	
	High	409	1159129	20	30975	1.19 (0.75-1.89)	0.464	
Physical Activity								0.650
	Low	341	798247	27	23389	1.55 (1.02-2.33)	0.038	
	Moderate	611	1789408	32	42241	1.52 (1.05-2.20)	0.027	
	High	562	1823065	21	39167	1.00 (0.64-1.57)	0.99	
Diet								0.968
	Healthy	935	2856079	51	72992	1.27 (0.95-1.70)	0.112	
	Unhealthy	1145	2796062	58	66169	1.36 (1.03-1.79)	0.028	
Diabetes								0.010
	Yes	461	440728	40	36479	1.08 (0.78-1.50)	0.644	
	No	1619	5211413	69	102682	1.52 (1.19-1.96)	0.001	
Hypertension								0.614
	Yes	1670	4087924	98	122365	1.30 (1.05-1.61)	0.015	
	No	407	1559937	11	16782	1.54 (0.82-2.87)	0.179	
Hyperlipidemia								0.044
	Yes	1301	2684075	91	116556	1.23 (0.99-1.53)	0.063	
	No	779	2968066	18	22605	1.96 (1.22-3.15)	0.006	
NSAIDs								0.676
	Yes	360	942313	7	8732	1.19 (0.55-2.56)	0.659	
	No	1720	4709828	102	130429	1.32 (1.07-1.62)	0.009	
Hypolipidemic drug								0.361
	yes	539	934428	81	100727	1.40 (0.87-2.25)	0.162	
	no	1541	4717713	28	38434	1.23 (0.99-1.53)	0.057	
Vitamin								0.583
	Yes	328	844741	19	20443	1.43 (0.88-2.32)	0.144	
	No	1752	4807400	90	118718	1.28 (1.03-1.60)	0.027	
Mineral								0.867
	Yes	415	1229229	14	20387	1.20 (0.69-2.08)	0.514	
	No	1665	4422912	95	118774	1.33 (1.07-1.65)	0.009	



Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, Hyperlipidemia, NSAID intake, multivitamin use, Hypolipidemic drug intake and intake of mineral supplements. HR, hazard ratio; CI, confidence interval; IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Given the interaction effects of diabetes and hyperlipidemia observed in the overall analysis of antithrombotic drug use, we conducted corresponding subgroup analyses for each drug class. The results indicate that the effect modification by these two metabolic abnormalities was selective and not universally observed across all medications. A significant effect modification by diabetes was observed for anticoagulants ($p = 0.019$). Given that warfarin was the predominant agent in this category (other anticoagulants were excluded from analysis due to insufficient sample size), further subgroup analysis confirmed that this interaction remained significant ($p = 0.015$). The increased risk associated with anticoagulants overall (HR = 1.68) and with warfarin specifically (HR = 1.64) was primarily observed in non-diabetic individuals. Furthermore, no significant effect modification by hyperlipidemia was detected for anticoagulants. No significant interactions with either diabetes or hyperlipidemia were found for antiplatelet agents (including low-dose aspirin, clopidogrel, and dipyridamole) (Supplementary Table 2).

Sensitivity Analysis

To validate the robustness of our findings, we conducted multiple sensitivity analyses. First, the association remained stable after additional adjustment for a history of cardiovascular disease (HR = 1.31, 95% CI: 1.08-1.61). Second, to assess potential reverse causality, we performed a lag exposure analysis. The association remained significant after excluding NGAP cases that occurred within the first year of follow-up (HR = 1.25, 95% CI: 1.01-1.54) (Supplementary Table 3). Finally, propensity score matching (PSM) analysis demonstrated that in a matched cohort of 55,694 participants (Supplementary Table 4), antithrombotic drug use was associated with a 37% increased risk (HR=1.37, 95% CI: 1.01-1.86).

Discussion

This large-scale cohort study examined the association between antithrombotic drug use and an increased risk of NGAP. Risk heterogeneity was observed across drug classes: anticoagulants as a class were associated with higher risk, with a non-sign ificant trend for warfarin, whereas among antiplatelet agents, only clopidogrel sho wed a significant association. Critically, the association was modified by comorbidi ties. The elevated risk was concentrated in individuals without diabetes or hyperlip idemia, an effect traced primarily to the anticoagulant class. Diabetes was the key modifier for anticoagulants (including warfarin), while hyperlipidemia's modifying effect was absent in this subgroup. No significant effect modification was observe

d for antiplatelet drugs.

This study is the first prospective cohort study to investigate the association between the use of antithrombotic drugs and NGAP. Although antithrombotic drugs are widely used, their relationship with the risk of developing NGAP has not been thoroughly explored. Previous research has primarily explored the effects of these drugs on cardiovascular and cerebrovascular diseases.[21,22] Other studies have focused on their role in the development and prognosis of acute pancreatitis.[10,11,23] Our study reveals a novel adverse effect. A key finding is the significant association specifically with the P2Y12 receptor antagonist clopidogrel, suggesting a drug-specific mechanism rather than a class effect, as other antiplatelet agents (aspirin and dipyridamole) showed no significant risk. Furthermore, prior studies on anticoagulation therapy and acute pancreatitis have primarily focused on evaluating its impact on prognosis, without investigating whether different metabolic statuses act as effect modifiers.[24] Therefore, our findings address a significant research gap by proposing that diabetes mellitus exerts a negative modifying effect on the association between warfarin use and the risk of NGAP.

We propose that clopidogrel may increase the risk of NGAP by impairing pancreatic microcirculation via antagonism of P2Y12 receptors on pericytes. While P2Y12 receptor inhibition in platelets is well understood, its role in vascular mural cells is crucial here.[25] Recent studies have shown that these receptors are also expressed on vascular smooth

muscle cells (VSMCs), where their activation inhibits the cAMP/protein kinase A pathway. This inhibition leads to dephosphorylation of the cytoskeletal regulator Cofilin, promoting actin depolymerization and enhanced cell motility.[26–29] Given the high homology between VSMCs and pericytes—collectively termed "mural cells"—and confirmed P2RY12 expression in pericytes,[30] pancreatic pericytes likely also express functional P2Y12 receptors. We hypothesize that basal signaling through these receptors helps maintain pericyte attachment and cytoskeletal plasticity by regulating cytoskeletal proteins, such as Cofilin. Clopidogrel antagonism disrupts this regulation, reducing cytoskeletal remodeling and increasing pericyte rigidity. This disruption compromises their capillary support function and connections with endothelial cells, thereby impairing the integrity of the microvascular barrier. The consequent increase in vascular permeability promotes the extravasation of inflammatory mediators and leukocyte infiltration, ultimately triggering or exacerbating local pancreatic inflammation.[31,32]

In contrast, aspirin acts by acetylating platelet COX-1 to inhibit thromboxane A2 synthesis—an effect highly localized to platelets.[33] Similarly, dipyridamole functions by inhibiting phosphodiesterase to elevate intracellular cAMP, which suppresses platelet activation and promotes vasodilation; it also elevates adenosine to enhance these effects.[34] Since neither agent directly interferes with the P2Y12 receptor signaling pathway—a crucial pathway in vascular wall cells such as pericytes—no significant association with AP risk was observed for either drug.

Users of anticoagulant medications demonstrated a significantly increased risk of NGAP (HR=1.37). Although the risk estimate for warfarin alone did not reach statistical significance, its trend was highly consistent with the overall anticoagulant risk, suggesting a potential real effect that is currently obscured by the limited statistical power in the subgroup analysis. An alternative explanation is that the overall risk is primarily driven by direct oral anticoagulants (DOACs), which we could not analyze separately but have been linked to an increased risk of pancreatitis in other studies.[35] Nevertheless, given the suggestive signal for warfarin and its widespread use, further investigation into its potential mechanisms is warranted. Mechanistically, warfarin, as a vitamin K antagonist, impairs the synthesis of coagulation factors and various other vitamin K-dependent proteins. A key example is Matrix Gla Protein (MGP), which is widely expressed in the vascular system and serves as a critical inhibitor of vascular calcification.[23,24,36] Warfarin may compromise pancreatic microvascular function by inhibiting MGP, among other pathways. This impairment, in turn, increases the tissue's susceptibility to inflammation.

Subgroup analysis revealed that the risk associated with warfarin was significantly modified by diabetes status (interaction $p = 0.015$), with the increased risk concentrated almost entirely in non-diabetic individuals. We propose a biologically plausible explanation: diabetes is often associated with a hypercoagulable state, which itself poses a risk for pancreatic microcirculatory impairment and AP.[37–39] In this context, warfarin's

anticoagulant effect may ameliorate the hypercoagulable state, thereby conferring a protective effect on the pancreatic microcirculation that offsets its potential direct risk. Conversely, in non-diabetics with normal baseline coagulation, the direct risk of warfarin becomes predominant. The traditional concept of "competing risks" provides a supplementary explanation, whereby the high baseline risk in diabetic patients may mask the additional risk from warfarin.[40] Overall, this finding underscores the necessity of considering the patient's underlying pathophysiology in drug safety evaluations, suggesting that the AP risk associated with warfarin is primarily relevant to individuals without diabetes.

Our study has several strengths, including its prospective design, large sample size, and extended follow-up period. We utilized propensity score matching to enhance intergroup comparability. Notably, our subgroup analyses systematically identified, for the first time, that diabetes status is a significant effect modifier of the warfarin-AP association. The most critical finding—that the risk was elevated primarily in low-risk individuals (e.g., those without diabetes)—holds profound clinical implications. This counterintuitive pattern serves as a clear warning, underscoring the imperative of conducting a thorough benefit-risk assessment before initiating antithrombotic therapy, even in patients perceived to be at low baseline risk, to avoid underestimating potential treatment-related hazards.

This study has several limitations. First, despite rigorous adjustment for known confounders using propensity score matching, residual confounding may persist due to the observational design. Second, analyses of specific antithrombotic drug subtypes, particularly those beyond anticoagulants and clopidogrel, may have been underpowered due to limited sample sizes. Consequently, while the data suggest potential risk heterogeneity, definitive conclusions for most subtypes cannot be drawn and require validation in larger studies. Third, outcome misclassification is possible due to reliance on medical coding. Finally, as the cohort was predominantly White (94.3%), the generalizability of our findings to other racial or ethnic groups may be limited, necessitating future validation in more diverse populations.

Conclusions

This large prospective cohort study establishes that antithrombotic medication use—particularly with clopidogrel—is associated with an increased risk of NGAP. Furthermore, it identifies underlying metabolic status as a key modifier of this risk. Strikingly, diabetes status exerts a negative modifying effect on the warfarin-associated risk, which was more pronounced in individuals without diabetes. This counterintuitive finding underscores the necessity of personalized risk assessment in clinical decision-making for antithrombotic therapy, with particular vigilance warranted in seemingly "healthy" populations. Future research should prioritize elucidating the underlying biological mechanisms and validating these findings at the level of specific drug subtypes

in additional high-quality cohorts.

Acknowledgements

We thank all participants and researchers from the UK Biobank who made the study possible.

Contributions

Chenyang Wei: Writing - original draft, Visualization, Investigation, Data curation, Formal analysis, Conceptualization. Jinyu Zhao: Writing - original draft, Methodology, Formal analysis. Ningning Mi: Investigation, Methodology, Formal analysis. Pengfei Li: Validation, Methodology. Zhengping An: Methodology. Sheng Chen: Visualization, Investigation. Yanyan Lin: Writing - review & editing. Ping Yue: Writing - review & editing. Jinqiu Yuan: Writing - review & editing, Supervision, Formal analysis. Wenbo Meng: Writing - review & editing, Supervision, Funding acquisition.

Funding

This work was supported by the Major Program of the Gansu Province Joint Scientific Research Fund (23JRRA1488); Major Scientific and Technological Innovation Project of Gansu Provincial Health Industry (GSWSQNPY2024-10); and the Lanzhou Talent Innovation and Entrepreneurship Project (2022-3-42).

Data Availability

UK Biobank is an open-access resource, and the study website https://www.ukbiobank.ac.uk/ provides information on available data and access procedures. Data sets used for analysis will be made available upon reasonable request.

Ethics approval and consent to participate

Each participant provided written informed consent before data collection. The UK Biobank obtained ethics approval from the National Research Ethics Committee (REC ID: 16/NW/0274).

Declaration of competing interests

The authors declared that no competing interests exist.

Reference

1. Lee PJ, Papachristou GI. New insights into acute pancreatitis. *Nat Rev Gastroenterol Hepatol*. 2019;16(8):479-496. doi:10.1038/s41575-019-0158-2

2. Zerem E. Treatment of severe acute pancreatitis and its complications. *World J Gastroenterol*. 2014;20(38):13879-13892. doi:10.3748/wjg.v20.i38.13879

3. Han K, Chen S, Song Y, et al. Burden of pancreatitis and associated risk factors in China, 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Chin Med J (Engl)*. 2022;135(11):1340-1347. doi:10.1097/CM9.0000000000002164

4. van Geenen EJM, van der Peet DL, Bhagirath P, Mulder CJJ, Bruno MJ. Etiology and diagnosis of acute biliary pancreatitis. *Nat Rev Gastroenterol Hepatol*. 2010;7(9):495-502. doi:10.1038/nrgastro.2010.114

5. Scherer J, Singh V, Pitchumoni CS, Yadav D. Issues in Hypertriglyceridemic Pancreatitis - An Update. *J Clin Gastroenterol*. 2014;48(3):195-203. doi:10.1097/01.mcg.0000436438.60145.5a

6. Szatmary P, Grammatikopoulos T, Cai W, et al. Acute Pancreatitis: Diagnosis and Treatment. *Drugs*. 2022;82(12):1251-1276. doi:10.1007/s40265-022-01766-4

7. Xie H, Jiang L, Peng J, Hu H, Han M, Zhao B. Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology. *Front Pharmacol*. 2025;16:1564127. doi:10.3389/fphar.2025.1564127

8. World Health Organization. *The Selection and Use of Essential Medicines, 2025: WHO Model List of Essential Medicines, 24th List*. World Health Organization; 2025. doi:10.2471/B09474

9. Zhang W, Yu E, Zhao W, Wu C, Ji X. Secondary prevention for intracranial atherosclerotic stenosis: Where we stand and challenges ahead. *J Transl Intern Med*. 2024;12(6):537-539. doi:10.1515/jtim-2024-0037

10. Maduzia D, Ceranowicz P, Cieszkowski J, Gałązka K, Kuśnierz-Cabala B, Warzecha Z. Pretreatment with Warfarin Attenuates the Development of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats. *Mol Basel Switz*. 2020;25(11):2493. doi:10.3390/molecules25112493

11. Kim DH, Ko D, Elizondo Alatorre C, et al. Low-dose aspirin use is associated with reduced 30- and 90-day mortality and overall improved outcomes in patients with acute pancreatitis: A multinational multicenter analysis. *Pancreatology*. 2025;25(7):1080-1085. doi:10.1016/j.pan.2025.09.022

12. Wilks AB, Douce D, Ades S, Cushman M, Zakai NA, Holmes CE. Bleeding Risk in a Cohort of Ambulatory Cancer Patients Receiving Outpatient Prophylactic Anticoagulation for Venous Thrombosis Prevention. *Blood*. 2019;134:709. doi:10.1182/blood-2019-128831

13. Chilbert MR, Gressel L, Lee L, Kersten B, Zammit K, Woodruff AE. Use of Prophylactic or Therapeutic Anticoagulation in Critically Ill Patients With Pre-existing Atrial Fibrillation. *Hosp Pharm*. 2025;60(3):232-238. doi:10.1177/00185787241295997

14. Yin Y, Wang L, Gao F, Liu L, Qi X. Anticoagulation Therapy for Splanchnic Vein Thrombosis Associated With Acute Pancreatitis: A Systematic Review and Meta-Analysis. *Clin Appl Thromb Off J Int Acad Clin Appl Thromb*. 2023;29:10760296231188718. doi:10.1177/10760296231188718

15. Norton W, Lazaraviciute G, Ramsay G, Kreis I, Ahmed I, Bekheit M. Current practice of anticoagulant in the treatment of splanchnic vein thrombosis secondary to acute pancreatitis. *Hepatobiliary Pancreat Dis Int HBPD INT*. 2020;19(2):116-121. doi:10.1016/j.hbpd.2019.12.007

16. Bian Y, Jiang H, Zheng J, Shao C, Lu J. Basic Pancreatic Lesions: Radiologic-pathologic Correlation. *J Transl Intern Med*. 2022;10(1):18-27. doi:10.2478/jtim-2022-

0003

17. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatol Off J Int Assoc Pancreatol IAP Al*. 2013;13(4 Suppl 2):e1-15. doi:10.1016/j.pan.2013.07.063

18. Löhr JM, Dominguez-Munoz E, Rosendahl J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). *United Eur Gastroenterol J*. 2017;5(2):153-199. doi:10.1177/2050640616684695

19. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779

20. UK Biobank. Available at: https://www.ukbiobank.ac.uk/. Accessed at: June 1. 2025.

21. Song PS, Park YH, Oh JH, et al. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. *Am J Cardiol*. 2021;150:47-54. doi:10.1016/j.amjcard.2021.03.053

22. Lu G, Tong Z, Ding Y, et al. Aspirin Protects against Acinar Cells Necrosis in Severe Acute Pancreatitis in Mice. *BioMed Res Int*. 2016;2016:6089430. doi:10.1155/2016/6089430

23. Zhao H, Liu H, Cheng J, et al. Early Prophylactic Anticoagulation and In-Hospital Mortality in Patients with Severe Acute Pancreatitis: A Retrospective Cohort Study. *Open Access Emerg Med OAEM*. 2025;17:289-300. doi:10.2147/OAEM.S539104

24. Danziger J. Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification. *Clin J Am Soc Nephrol CJASN*. 2008;3(5):1504-1510. doi:10.2215/CJN.00770208

25. JIA Min, LI Yi, GUO Qi-qi, WENG Huan-ze, CHEN Yu-long. The research progress of P2Y receptors and its antagonists in cardiovascular diseases. Chinese Pharmacological Bulletin, 2021, 37(12): 1629-1633. https://html.rhhz.net/ZGYLXTB/html/202112001.htm

26. Wu XM, Zhang N, Li JS, Yang ZH, Huang XL, Yang XF. Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis. *Purinergic Signal*. 2023;19(1):265-272. doi:10.1007/s11302-021-09839-x

27. Wihlborg AK, Wang L, Braun OO, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. *Arterioscler Thromb Vasc Biol*. 2004;24(10):1810-1815. doi:10.1161/01.ATV.0000142376.30582.ed

28. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. *Biochem J*. 1998;336 (Pt 3)(Pt 3):513-523. doi:10.1042/bj3360513

29. Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C, Gadeau AP. Nucleotide receptors involved in UTP-induced rat arterial smooth muscle cell migration. *Circ Res*. 2002;90(6):678-681. doi:10.1161/01.res.0000013700.98464.8e

30. Barnett SN, Cujba AM, Yang L, et al. An organotypic atlas of human vascular cells. *Nat Med*. 2024;30(12):3468-3481. doi:10.1038/s41591-024-03376-x

31. Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. *Br J Surg*. 2006;93(5):518-530. doi:10.1002/bjs.5316

32. Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute

pancreatitis. *J Hepatobiliary Pancreat Surg*. 2001;8(3):187-194. doi:10.1007/s005340170015

33. Midttun M, Grauholt AM, Grande P. [Thrombocyte aggregation and serum thromboxane in patients with acute myocardial infarction]. *Ugeskr Laeger*. 1990;153(1):25-26.

34. Ali Hassan R, Patel P. Dipyridamole. In: *StatPearls*. StatPearls Publishing; 2025. Accessed December 21, 2025. http://www.ncbi.nlm.nih.gov/books/NBK554455/

35. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. *Clin Gastroenterol Hepatol*. 2007;5(6):648-661.e3. doi:10.1016/j.cgh.2006.11.023

36. Willems BAG, Vermeer C, Reutelingsperger CPM, Schurgers LJ. The realm of vitamin K dependent proteins: Shifting from coagulation toward calcification. *Mol Nutr Food Res*. 2014;58(8):1620-1635. doi:10.1002/mnfr.201300743

37. Carr ME. Diabetes mellitus: a hypercoagulable state. *J Diabetes Complications*. 2001;15(1):44-54. doi:10.1016/s1056-8727(00)00132-x

38. Chung KH, Cho IR, Choi YH, et al. Association between diabetic status and risk of acute pancreatitis: A nationwide population-based study. *J Evid-Based Med*. 2024;17(3):588-596. doi:10.1111/jebm.12637

39. Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. *Eur J Gastroenterol Hepatol*. 2013;25(2):225-231. doi:10.1097/MEG.0b013e32835af154

40. Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. *PloS One*. 2012;7(12):e53224. doi:10.1371/journal.pone.0053224